脱细胞真皮基质的使用可能不增加即刻假体植入乳房再造的30天并发症:一项10177例的多机构分析
基于美国外科医师学会国家外科质量改进计划2008至2022年数据库,纳入10177例因肿瘤行即刻假体植入乳房再造的女性患者,比较脱细胞真皮基质(ADM)辅助与非ADM手术的30天并发症。多因素分析和倾向性评分匹配显示,ADM使用与手术并发症(比值比0.93,95%置信区间0.75-1.16,P=0.52)或内科并发症(比值比0.87,95%置信区间0.59-1.26,P=0.46)风险升高无关。
要点
- 10177例中45%(n=4605)接受ADM辅助DTI,55%(n=5572)未使用ADM。
- 手术并发症率ADM组4.7% vs 非ADM组5.5%(P=0.08),无显著差异。
- 校正混杂因素后ADM未增加手术或内科并发症风险。
核心结论
- 在即刻假体植入乳房再造中使用ADM与短期并发症风险升高无关,支持其在临床实践中继续使用。
研究设计与样本
- 基于美国外科医师学会国家外科质量改进计划数据库2008至2022年的多机构分析,纳入因肿瘤行即刻假体植入乳房再造的女性患者10177例,分为ADM辅助组和非ADM组,比较30天术后并发症,采用多因素分析和倾向性评分匹配。
主要发现
- ADM组平均年龄52±12岁 vs 非ADM组51±11岁(P=0.190)。
- ADM组肥胖21.5% vs 非ADM组26%(P<0.001),高血压20.5% vs 2.6%(P=0.01),糖尿病4.8% vs 5.1%(P=0.002),吸烟史6.4% vs 10.1%(P<0.001)。
- 手术并发症率ADM组4.7% vs 非ADM组5.5%(P=0.08),其中浅表感染2.0% vs 2.4%(P=0.19),深部感染0.6% vs 0.9%(P=0.17),伤口裂开0.8% vs 1.0%(P=0.24),出血0.6% vs 0.7%(P=0.54)。
- 内科并发症率ADM组1.4% vs 非ADM组1.7%(P=0.27)。
- 校正混杂因素后手术并发症比值比0.93(95%置信区间0.75-1.16,P=0.52),内科并发症比值比0.87(95%置信区间0.59-1.26,P=0.46)。
临床怎么用
- 作者认为ADM在即刻假体植入乳房再造中不增加短期并发症风险,支持其在临床实践中继续使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Direct-to-implant (DTI) breast reconstruction offers immediate aesthetic and psychological benefits, but the role of acellular dermal matrix (ADM) remains debated. Using a multi-institutional database, this study evaluates and compares outcomes between ADM-assisted and non-ADM DTI procedures. METHODS: The American College of Surgeons National Surgical Quality Improvement Program database from 2008 to 2022 was queried to identify female patients who underwent DTI breast reconstruction for oncological purposes. Patients were divided into 2 groups: DTI breast reconstruction with ADM and without. Thirty-day postoperative complications were compared using multivariate analysis and propensity score matching. RESULTS: Among 10,177 patients, 45% (n = 4605) underwent ADM-assisted DTI, while 55% (n = 5572) had non-ADM DTI. While both groups showed comparable mean ages (ADM: 52 ± 12 years vs non-ADM: 51 ± 11 years; P = 0.190), ADM patients were significantly less likely to present with comorbidities such as obesity (ADM: 21.5% vs non-ADM: 26%; P < 0.001), hypertension (20.5% vs 2.6%; P = 0.01), diabetes (4.8% vs 5.1%; P = 0.002), and smoking history (6.4% vs 10.1%; P < 0.001). Still, surgical complication rates were comparable (ADM: 4.7%, non-ADM: 5.5%; P = 0.08), including superficial infections (2.0% vs 2.4%; P = 0.19), deep infections (0.6% vs 0.9%; P = 0.17), wound dehiscence (0.8% vs 1.0%; P = 0.24), and bleeding (0.6% vs 0.7%; P = 0.54). Medical complications were generally rare and also showed no significant differences (ADM: 1.4%, non-ADM: 1.7%; P = 0.27). Confounder-adjusted multivariable analysis and propensity score matching confirmed no increased risk of surgical (odds ratio 0.93, 95% confidence interval 0.75-1.16, P = 0.52) or medical complications (odds ratio 0.87, 95% confidence interval 0.59-1.26, P = 0.46). CONCLUSIONS: The use of ADM in DTI breast reconstruction is not associated with a higher risk of short-term complications, supporting its continued use in clinical practice. This information is crucial for surgeons and patients in making informed decisions regarding the incorporation of ADM in DTI breast reconstruction. BACKGROUND: Direct-to-implant (DTI) breast reconstruction offers immediate aesthetic and psychological benefits, but the role of acellular dermal matrix (ADM) remains debated. Using a multi-institutional database, this study evaluates and compares outcomes between ADM-assisted and non-ADM DTI procedures. METHODS: The American College of Surgeons National Surgical Quality Improvement Program database from 2008 to 2022 was queried to identify female patients who underwent DTI breast reconstruction for oncological purposes. Patients were divided into 2 groups: DTI breast reconstruction with ADM and without. Thirty-day postoperative complications were compared using multivariate analysis and propensity score matching. RESULTS: Among 10,177 patients, 45% (n = 4605) underwent ADM-assisted DTI, while 55% (n = 5572) had non-ADM DTI. While both groups showed comparable mean ages (ADM: 52 ± 12 years vs non-ADM: 51 ± 11 years; P = 0.190), ADM patients were significantly less likely to present with comorbidities such as obesity (ADM: 21.5% vs non-ADM: 26%; P < 0.001), hypertension (20.5% vs 2.6%; P = 0.01), diabetes (4.8% vs 5.1%; P = 0.002), and smoking history (6.4% vs 10.1%; P < 0.001). Still, surgical complication rates were comparable (ADM: 4.7%, non-ADM: 5.5%; P = 0.08), including superficial infections (2.0% vs 2.4%; P = 0.19), deep infections (0.6% vs 0.9%; P = 0.17), wound dehiscence (0.8% vs 1.0%; P = 0.24), and bleeding (0.6% vs 0.7%; P = 0.54). Medical complications were generally rare and also showed no significant differences (ADM: 1.4%, non-ADM: 1.7%; P = 0.27). Confounder-adjusted multivariable analysis and propensity score matching confirmed no increased risk of surgical (odds ratio 0.93, 95% confidence interval 0.75–1.16, P = 0.52) or medical complications (odds ratio 0.87, 95% confidence interval 0.59–1.26, P = 0.46). CONCLUSIONS: The use of ADM in DTI breast reconstruction is not associated with a higher risk of short-term complications, supporting its continued use in clinical practice. This information is crucial for surgeons and patients in making informed decisions regarding the incorporation of ADM in DTI breast reconstruction.
引用
- Knoedler S, Klimitz FJ, Friedrich S, et al. The Use of Acellular Dermal Matrix May Not Increase 30-Day Complications in Direct-to-Implant Breast Reconstruction: A Multi-institutional Analysis of 10,177 Cases. Ann Plast Surg. 2025. PMID: 39874559. doi:10.1097/SAP.0000000000004234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。